Durvalumab
Drug
Celgene Corporation
Total Payments
$3.3M
Transactions
132
Doctors
14
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $3.3M | 132 | 14 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 131 | 100.0% |
| Food and Beverage | $150.91 | 1 | 0.0% |
Payments by Type
Research
$3.3M
131 transactions
General
$150.91
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MEDI4736-MDS-001 | Celgene Corporation | $986,405 | 2 |
| MEDI4736-NHL-001 | Celgene Corporation | $723,409 | 4 |
| MEDI4736-MM-001 | Celgene Corporation | $519,318 | 0 |
| MEDI4736-MM-005 | Celgene Corporation | $316,240 | 3 |
| MEDI4736-MM-003 | Celgene Corporation | $297,009 | 2 |
| DV-CL-MM-PI-006524 | Celgene Corporation | $173,714 | 0 |
| MEDI4736-MM-002 | Celgene Corporation | $164,905 | 2 |
| MEDI4736-DLBCL-001 | Celgene Corporation | $91,084 | 1 |
| DV-CL-PLASM-PI-008059 | Celgene Corporation | $39,898 | 0 |
| DV-CL-AML-PI-007599 | Celgene Corporation | $14,500 | 0 |
| DV-CL-CTCL-PI-007921 | Celgene Corporation | $249.48 | 0 |
Top Doctors Receiving Payments for Durvalumab
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Concord, NC | $3.3M | 116 |
| , MD | Internal Medicine | Seattle, WA | $2,976 | 2 |
| , M.D | Hematology | Atlanta, GA | $2,559 | 1 |
| , M.D | Internal Medicine | Rochester, NY | $1,488 | 1 |
| , M.D | Hematology & Oncology | Rochester, MN | $1,488 | 1 |
| , M.D | Hematology & Oncology | Houston, TX | $1,488 | 1 |
| , MD | Hematology & Oncology | Boston, MA | $1,488 | 1 |
| , M.D | Hematology | Rochester, MN | $1,488 | 1 |
| , MD, PHD | Internal Medicine | New York, NY | $1,488 | 1 |
| , MD | Medical Oncology | New York, NY | $1,488 | 1 |
| , D.O | Hematology & Oncology | Morristown, NJ | $834.00 | 2 |
| , MD | Hematology & Oncology | Boston, MA | $417.00 | 1 |
| , MD | Hematology & Oncology | Southington, CT | $417.00 | 1 |
| , MD | Hematology & Oncology | Houston, TX | $417.00 | 1 |
| , M.D | Hematology | Salt Lake City, UT | $150.91 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $3.3M
Product Information
- Type Drug
- Total Payments $3.3M
- Total Doctors 14
- Transactions 132
About Durvalumab
Durvalumab is a drug associated with $3.3M in payments to 14 healthcare providers, recorded across 132 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2017. In 2017, $3.3M was paid across 132 transactions to 14 doctors.
The most common payment nature for Durvalumab is "Unspecified" ($3.3M, 100.0% of total).
Durvalumab is associated with 11 research studies, including "MEDI4736-MDS-001" ($986,405).